ADMA Biologics ADMA shares have skyrocketed 275.7% in a year against the industry’s decline of 14.3%. The stock has also ...

(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Dermatomyositis is a chronic autoimmune disease characterised by muscle weakness, skin lesions, and systemic complications.

I was diagnosed with Graves' disease, an autoimmune disorder. Going sober and trying an anti-inflammatory diet reduced my ...

Fred Hutch grew from a regional cancer center into a world-class biomedical research and clinical care institution known for ...